Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 5/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4956540 | 0.85 | DPP4 (0.55) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL8289061 | 0.85 | DPP4 (0.55) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL8289039 | 0.81 | DPP4 (0.68) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL14282750 | 0.78 | DPP4 (0.51) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL5772718 | 0.78 | DPP4 (0.52) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL5772714 | 0.78 | DPP4 (0.52) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL4917079 | 0.76 | DPP4 (0.53) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL5188904 | 0.76 | DPP4 (0.53) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL4954853 | 0.74 | DPP4 (0.54) | DPP4DPP7DPP9DPP8 | |
| SCHEMBL4955354 | 0.74 | DPP4 (0.68) | DPP4DPP7DPP9DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | DPP4 1/4885DPP7 2/4885DPP9 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.